Format

Send to

Choose Destination
See comment in PubMed Commons below
Future Oncol. 2005 Feb;1(1):79-92.

3p21.3 tumor suppressor cluster: prospects for translational applications.

Author information

1
Department of Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Unit 445, PO Box 301402, Houston, Texas, TX 77230-1402, USA. lji@mdanderson.org

Abstract

Chromosomal abnormalities at the 3p21.3 region, including homozygous deletions and loss of heterozygosity and expressional deficiencies in 3p21.3 genes including transcriptional silences by promoter hypermethylation, altered mRNA splicing and aberrant transcripts, and lost or defect protein translation and post-translational modifications, are frequently found in most human cancers. Inactivation of 3p21.3 genes in primary tumors affects a wide spectrum of key biological processes such as cell proliferation, cell cycle kinetics, signaling transduction, ion exchange and transportation, apoptosis and cell death, and demonstrates the molecular signatures of carcinogenesis. Restoration of defective 3p21.3 genes with several wild-type 3p21.3 genes suppresses tumor cell growth both in vitro and in vivo. These findings suggest several 3p21.3 genes as potential tumor suppressors and implicates these 3p21.3 genes for future development as biomarkers for the early detection and diagnosis of cancer, and as prognostic and therapeutic tools for cancer prevention and molecular cancer therapy.

PMID:
16555978
DOI:
10.1517/14796694.1.1.79
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center